ValiRx acquires assets from Imagen

14 June 2023

UK-based ValiRx (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, has acquired the scientific assets of Imagen Therapeutics from its appointed liquidators.

Imagen was a pharma services company offering a patient-derived screening platform suitable for large global clients. Total consideration paid for its assets was a single cash payment of £170,000 ($215,000) to the liquidators.

"This is an important step towards our ambition to make our assays more closely aligned to a complex human system"According to ValiRx, the deal represents a significant discount to the original commercial value of the assets acquired, which include an extensive biobank of patient-derived cells, a comprehensive range of laboratory equipment required for analysis and application of the cells. Among these items are some that are in the financial plan for Inaphaea BioLabs, a firm that span out of ValiRx this year as a wholly-owned subsidiary.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK